Glibenclamide does not prevent action potential shortening induced by ischemia in anesthetized rabbits but reduces ischemia induced arrhythmias

Journal of Molecular and Cellular Cardiology

Volumn 30, Issue 5, 1998, Pages 999-1008

  Barrett, Terrance D ^a   Walker, Michael J A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Action potential duration; Antiarrhythmic; Arrhythmias; Class III; Glibenclamide; MAP; Monophasic action potentials; Myocardial ischemia; Rabbit

Indexed keywords

GLIBENCLAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE ACTION POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0032077550     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1998.0664     Document Type: Article

References (35)

1. + channel inhibitor, glibenclamide, to reduce reperfusion-induced or ischaemia arrhythmias in rat hearts. Br J Pharmacol 100: P438.
2. BALLAGI-PORDÁNY G, KÖSZEGHY A, KOLTAI M-Z, ARANYI Z, POGÁTSA G, 1990. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Res Clin Practice 8: 109-114.
3. BARRETT TD, WALKER MJA, 1996. Glibenclamide possesses transient, ischemia selective Class III antiarrhythmic actions but does not prevent ischemia induced arrhythmias. Br J Pharmacol 119: P116.
4. BARRETT TD, MACLEOD BA, WALKER MJA, 1997a. A model of myocardial ischemia for the simultaneous assessment of electrophysiological changes and arrhythmias in intact rabbits. J Pharmacol Toxicol Meth 37: 27-36.
5. BARRETT TD, HAYES ES, YONG SL, WALKER ML, BEATCH GN, WALKER MJA, 1997b. Ischemic selective electrophysiological and antiarrhythmic actions of RSD1019 in ischemic cardiac tissue. J Mol Cell Cardiol 29: P197.
6. BILLMAN GE, AVENDANO CE, HALLIWILL JR, BURROUGHS JM, 1993. The effects of the ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs. J Cardiovasc Pharmacol 21: 197-204.
7. BRIL A, FOREST MC, CHEVAL B, LANDAIS L, GOUT B, 1994. Effects of zatebradine, a specific bradycardic agent, on ischemic-induced arrhythmias in anesthetized rabbits. Pharmacology 48: 308-319.
8. BURTON T, CHAKRABARTY S, FLUCK DS, FLORES NA, SHERIDAN DJ, 1992. Effects of cicletanine on haemo-dynamics, arrhythmias and extent of necrosis during coronary ligation in rabbits. Br J Pharmacol 107: 1135-1137.
9. CHI L, UPRICHARD ACG, LUCCHESI BR, 1989. Failure of glibenclamide to protect against ventricular fibrillation in a canine model of myocardial infarction. J Mol Cell Cardiol 21: P266.
10. + channels protect the myocardium against ischemia/reperfusion damage. Circ Res 69: 571-581.
11. CURTIS MJ. 1991. The rabbit dual coronary perfusion model: a new method for assessing the pathological relevance of individual products of the ischemic milieu: role of potassium in arrhythmogenesis. Cardiovasc Res 25: 1010-1022.
12. CURTIS MJ, WALKER MJA, 1988. Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischemia. Cardiovasc Res 22: 656-665.
13. CURTIS MJ, HEARSE DJ, 1989. Ischemia-induced and reperfusion-induced arrhythmias differ in their sensitivity to potassium: implications for mechanisms of initiation and maintenance of ventricular fibrillation. J Mol Cell Cardiol 21: 21-40.
14. DICKENSON DR, DAVIS DR, BEATCH GN, 1997. Development and evaluation of a fully automated monophasic action potential analysis program. Med Biol Eng Comput 56: 653-660.
15. FARKAS A, LEPRAN I, PAPP JG, 1996. Effects of almokalant a specific inhibitor of IKr on myocardial ischaemia-reperfusion induced arrhythmias in rabbits. Acta Physiol Hungarica 84: 281-282.
16. + channels during metabolic stress in cardiac muscle. J Pharmacol Exp Ther 266: 456-467.
17. + loss in a model of ischemia in perfused guinea-pig hearts in vitro. Eur J Pharmacol 220: 231-236.
18. + release and the development of arrhythmias during hypoxic perfusion in isolated rat hearts. Pflüger Arch 418: R90.
19. INQUE F, MACLEOD BA, WALKER MJA, 1982. Intracellular potential changes following coronary artery occlusion in isolated perfused rat hearts. Can J Physiol Pharmacol 62: 658-664.
20. LAZZARA R, EL-SHERIF N, HOPE RR, SCHERLAG BJ, 1978. Ventricular arrhythmias and electrophysiological consequences of myocardial ischemia and infarction. Circ Res 42: 740-749.
21. MACKENZIE I, SAVILLE VL, WATERFALL JF, 1993. Differential Class III and glibenclamide effects on action potential duration in guinea-pig papillary muscle during normoxia and hypoxia/ischemia. Br J Pharmacol 110: 531-538.
22. ATP channel modulators during regional ischemia. Am J Physiol 271: H140-H147.
23. MORITANI K, MIYAZAKI T, MIYOSHI S, ASANAGI M, ZHAO L, MITAMURA H, OGAWA S, 1994. Blockade of ATP-sensitive potassium channels by 5-hydroxydecanoate suppresses monophasic action potential shortening during regional myocardial ischemia. Cardiovasc Drugs Ther 8: 749-756.
24. POGÁTSA G, KOLTAI MZ, BALKÁNYI I, DÉVAI J, KISS V, 1985. Effects of various hypoglycemic sulfonylureas on the cardiotoxicity of glycosides. Eur J Clin Pharmacol 28: 367-370.
25. POGÁTSA G, KOLTAI MZ, BALKÁNYI I, DÉVAI I, KISS V, KÖSZEGHY A, 1988. The effects of various hypoglycemic sulfonylureas on the cardiotoxicity of glycosides and arrhythmogenic activity due to myocardial ischemia. Acta Physiologica Hungarica 71: 243-250.
26. REES SA, CURTIS MJ, 1995. Pharmacological analysis in rat of the role of the ATP-sensitive potassium channel as a potential target for antifibrillatory intervention in acute myocardial ischemia. J Cardiovasc Pharmacol 26: 280-288.
27. + channel blockers on the action potentials of hypoxic rabbit myocardium. Br J Pharmacol 106: 924-930.
28. SAINT MK, ABRAHAM S, MACLEOD BA, MCGOUGH MJ, YOSHIDA N, WALKER MJA, 1992. Ischemic but not reperfusion arrhythmias depend upon serum potassium concentration. J Mol Cell Cardiol 24: 701-709.
29. SMALLWOOD JK, ERTEL PJ, STEINBERG MI, 1990. Modification by glibenclamide of the electrophysiological consequences of myocardial ischemia in dogs and rabbits. Naunyn-Schmiedeberg's Arch Pharmacol 342: 214-220.
30. TAGGART P, SUTTON PMI, SPEAR DW, DRAKE HF, SWANTON HR, EMANUEL RW, 1988. Simultaneous endocardial and epicardial monophasic action potential recordings during brief periods of coronary artery ligation in the dog: influence of adrenaline, beta blockade and alpha blockade. Cardiovasc Res 22: 900-909.
31. + loss during hypoxia, ischemia, and metabolic inhibition in mammalian ventricle. Circ Res 69: 623-637.
32. WALKER MJA, CURTIS MJ, HEARSE DJ, CAMPBELL RWF, JANSE MJ, YELLON DM, COBBE SM, COKER SJ, HARNESS JB, HARRON DWG, HIGGINS AJ, JULIAN DG, LAB MJ, MANNING AS, NORTHOVER BJ, PARRATT JR, RIEMERSMA RA, RIVA E, RUSSEL RC, SHERIDAN DJ, WINSLOW E, WOODWARD B, 1988. The Lambeth conventions: guidelines for the study of arrhythmias in ischaemia, infarction and reperfusion. Cardiovasc Res 22: 447-455.
33. WILDE AAM, JANSE MJ, 1994. Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res 28: 16-24.
34. + loss, reduction in repolarization time, and tissue ATP levels during myocardial hypoxia and ischemia. Circ Res 72: 560-570.
35. ATP channels. Circulation 89: 1229-1236.